Navigation Links
Study Examines Media Preferences of Life Scientists in Applied Markets
Date:1/4/2008

ARLINGTON, Va., Jan. 4 /PRNewswire/ -- Faced with modest growth in the traditional life science market, suppliers are turning their attention to opportunities in agricultural, biodefense and molecular diagnostics. To help companies navigate these unfamiliar waters, leading research and advisory firm BioInformatics, LLC today released its latest report examining the marketing and media preferences of scientists working in these dynamic markets. The report, "Marketing to Life Scientists: Capturing Customers' Attention in Applied Markets" highlights the importance of effective marketing in capturing mindshare in markets where product differentiation can be hard to achieve.

A complimentary Executive Summary of the report is available at: http://www.gene2drug.com/reports/default.asp?action=details&report_id=186

"This report can help life science companies determine the right combination of marketing messages and tactics to efficiently reach their target audience in these applied markets," said Tamara Zemlo, PhD, Director of Syndicated Research at BioInformatics, LLC. "Scientists working in these fields share many similarities with those in basic research and drug discovery, but there are also some striking differences that marketers can exploit for optimal effectiveness."

The scientists surveyed also ranked the effectiveness of their suppliers' marketing programs in terms of "best" Web site, print catalog, exhibits, print advertising and sales force. While hundreds of companies were mentioned, market leaders such as Bio-Rad Laboratories (Amex: BIO), BD Biosciences (NYSE: BDX), Invitrogen (Nasdaq: IVGN), Sigma-Aldrich (Nasdaq: SIAL), Thermo Fisher Scientific (NYSE: TMO), and New England Biolabs all received exceptionally high rankings in multiple categories.

"When the data is analyzed by segment, however, it's clear that some firms have been more successful than others in raising awareness of their brands in the agricultural, biodefense and molecular diagnostics markets," observed Zemlo.

Key findings of the report will be shared in a complimentary Webinar presented on January 15, 2008 at 1:00 p.m. ET. To register to attend the Webinar, please email webinars@gene2drug.com.

ABOUT BIOINFORMATICS, LLC

BioInformatics, LLC is the premier research and advisory firm serving the life science industry. By leveraging our professional social network of more than 35,000 biomedical researchers, we have supported more than 300 companies and provided insights that lead to better business decisions. Our assignments include assessing the size and attractiveness of markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning.

For more information, please contact:

Catherine Seguin

Director of Communications

BioInformatics, LLC

2111 Wilson Blvd., Suite 250

Arlington, VA 22201

703.778.3080 x13 (phone)

c.seguin@gene2drug.com

http://www.gene2drug.com/


'/>"/>
SOURCE BioInformatics, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Triage study challenges notions of emergency medical response to disaster
2. Federally-Funded Study Shows More Women Can Avoid Hysterectomy for Common Problem
3. Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
4. Study Reaffirms Superiority of Trofile(TM) Assay
5. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
6. Genmab Announces Details of Planned Ofatumumab Phase II Study in Multiple Sclerosis
7. Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding
8. National Cancer Institute Study to Determine the Optimal Time for CLL Patients to Begin Treatment
9. Berlin Heart Enrolls First Patient in US Multi-Center EXCOR(R) Pediatric VAD IDE Study
10. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
11. STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... ... May 22, 2017 , ... Stratevi, a boutique firm ... the East Coast. It has opened an office in downtown Boston at 745 Atlantic ... it increasingly more important to generate evidence on the value they provide, not just ...
(Date:5/21/2017)... ... May 19, 2017 , ... Ovation Fertility ... the American Association of Bioanalysts (AAB) and the College of Reproductive Biology (CRB) ... reinforces AAB’s commitment to excellence in clinical laboratory services and regulations. , ...
(Date:5/19/2017)... ... May 19, 2017 , ... The University ... researchers with technologies ripe for commercialization, and who are affiliated with the 21 ... to submit proposals. QED, now in its tenth round, is the first multi-institutional ...
(Date:5/18/2017)... ... , ... Clinical Supplies Management (“CSM”), a Great Point Partners II (“GPP”) portfolio ... CSM has doubled in size over the past six months with the acquisition of ... Gasper joins CSM as Chief Financial Officer. Roger has over 25 years of ...
Breaking Biology Technology:
(Date:4/24/2017)... 2017 Janice Kephart , former ... Strategy Partners, LLP (IdSP) , today issues the ... Trump,s March 6, 2017 Executive Order: Protecting ... can be instilled with greater confidence, enabling the ... refugee applications are suspended by until at least ...
(Date:4/13/2017)... April 13, 2017 According to a new market ... Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, ... Market is expected to grow from USD 14.30 Billion in 2017 to ... of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
Breaking Biology News(10 mins):